DarioHealth DRIO 深 沪
已收盘 08-14 16:00:00 美东时间
7.585
+0.255
+3.48%
华盛通- 最 高7.915
- 今 开7.24
- 成交量 5321股
- 最 低 7.24
- 昨 收 7.33
- 总市值 7428.26万
- 52周最高 17.7437
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 5.8445
- 委 比 0.00%
- 总股本 979.34万
- 历史最高 1697760.00
- 量 比 0.21
- 振 幅 9.21%
- 历史最低 5.8445
- 每 手 1
- 风险率 2.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
TD Cowen Maintains Hold on DarioHealth, Lowers Price Target to $8
TD Cowen analyst Charles Rhyee maintains DarioHealth (NASDAQ:DRIO) with a Hold and lowers the price target from $11 to $8.
08-12 23:17
DarioHealth Q2 Adj. EPS $(0.72) Beats $(1.22) Estimate, Sales $5.177M Miss $5.923M Estimate
DarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.22) by 40.98 percent. This is a 82.44 percent increase over losses of $(4.10) per share from the same period last year. The company reported quarterly sales of $5.177 million whi...
08-11 18:33
DarioHealth 2026财年第二季度业绩：尽管营收下滑但利润率扩大
DarioHealth（NASDAQ: DRIO）公布2026财年第二季度营收为520万美元，低于上年同期的540万美元，主因是公司减少了部分与制药相关的业务。毛利率从55.2%提升至61.7%，营业费用下降21%，GAAP营业亏损收窄至650万美元。截至6月底，公司持有的现金、现金等价物及短期存款约为1400万美元，随后在7月净融资2280万美元。新增的多病种服务合同及客户拓展预计将在2026年晚些时候开始贡献业绩，并在2027年带来更显著的成效。
08-11 10:43
DarioHealth Q2 2026 earnings: Margin expands despite lower revenue
DarioHealth (NASDAQ: DRIO) reported Q2 2026 revenue of $5.2 million, down from $5.4 million a year earlier as it moved away from certain pharmaceutical-related work. Gross margin rose to 61.7% from 55.2%, while operating expenses fell 21% and the GAAP operating loss narrowed to $6.5 million. The company ended June with about $14.0 million in cash, equivalents and short-term deposits, then raised $22.8 million net in July. New multi-condition cont
08-11 10:42
DarioHealth Launches GLP-1 Program, With Commercial Availability Expected Fall 2026, With Revenue Contribution From Late 2026 And Ramping Through 2027
First commercial offering from Dario's collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside Dario's chronic care platform Launch addresses a market in which employers and health plans are reducing GLP-1 coverage and members ar...
07-30 19:37
DarioHealth prices $23.5M registered direct offering
DarioHealth (NASDAQ: DRIO) said on Wednesday it priced a $23.5M registered direct offering of 3.45M common shares at $6.80 per share, in compliance with Nasdaq rules. The offering includes the purcha...
07-22 20:12
DarioHealth Selected By Fortune 50 Employer To Offer Its Integrated Digital Cardiometabolic Care Platform
DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platf...
07-16 19:36
Dario预计AI引擎DarioIQ™将推动现有客户经常性收入增长10%-15%
数字健康公司DarioHealth Corp．近日表示，其专有的人工智能平台DarioIQ™的广泛部署，预计将推动来自现有客户的年度B2B2C经常性收入增长...
07-13 21:03
